MANKIND2023-04-012023-06-30 MANKIND2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member MANKIND2023-06-30 MANKIND2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member MANKIND2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member MANKIND2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member MANKIND2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543904 MANKIND NOTLISTED Mankind Pharma Limited Equity 2023-04-01 2024-03-31 2023-08-02 2023-07-18 INR Lakhs First quarter 16:00:00 17:55:00 2023-08-02 2023-08-02 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Consolidated 25786175000.00 586189000.00 26372364000.00 4866869000.00 3514450000.00 -181740000.00 5529101000.00 63398000.00 873549000.00 5509338000.00 20174965000.00 6197399000.00 0.00 6197399000.00 1447734000.00 -144963000.00 1302771000.00 0.00 4894628000.00 0.00 0.00 0.00 47256000.00 4941884000.00 -32963000.00 4908921000.00 4835659000.00 73262000.00 400588000.00 1 12.15 12.14 0.00 0.00 12.15 12.14 1. These unaudited consolidated financial results of the Holding Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standard) rules, 2015, as amended. The said unaudited consolidated financial results represent the results of Mankind Pharma Limited ( Holding Company ) and its subsidiaries (the Holding Company and its subsidiaries together referred to as the Group ), its associates and joint ventures for the quarter ended June 30, 2023. 2. These unaudited consolidated financial results have been reviewed by the Audit Committee at its meeting held on August 02, 2023 and have been approved by Board of Directors at its meeting held on August 02, 2023. These unaudited consolidated financial results have been subjected to limited review by the joint statutory auditors of the Holding Company in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ( the Regulations ). The joint statutory auditors have issued an unmodified report on the these unaudited consolidated financial results. 3. The Group is primarily engaged in manufacturing and trading of pharmaceuticals and healthcare products. Accordingly, the Group has only one reportable segment 'Pharmaceuticals' and disclosures as per Ind AS 108 Operating Segments are not applicable. 4. During the quarter ended June 30, 2023, the Income Tax Department (‘the department’) conducted a search under section 132 of the Income Tax Act, 1961 at Holding Company’s registered office, corporate office, few of its manufacturing locations and other premises and few of its group entities and residence of few of its employees/key managerial personnel. During the search proceedings, the Holding Company provided necessary information and responses to the department. Also, the department has taken certain documents, data backups and other information for further investigation. The business and operations of the Holding Company continued without any disruptions and no demands have been raised on the Holding Company as of date. Based on the foregoing and having regard to the matters of inquiry during the search proceedings stated above, management is of the view that no material adjustments are required to these unaudited consolidated financial results in this regard. 5. On May 09, 2023, the equity shares of the Holding Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). Accordingly, these are first quarter results after the results for the quarter and year ended March 31, 2023 and consequently, comparative numbers for the quarter ended June 30, 2022 were not subjected to a review by joint statutory auditors of the Holding Company and are prepared by the management and approved by the Board of Directors of Holding Company. 6. The figures for the quarter ended March 31, 2023 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2023 and audited year to date figures up to the nine months period ended December 31, 2022. Other expenses 5509338000.00 Re-measurement gain/ (loss) on defined benefit plans -42588000.00 Share of other comprehensive income/ (loss) of associates and joint ventures 168000.00 Change in the fair value of equity investments at FVTOCI 908000.00 -41512000.00 -14446000.00 Exchange differences in translating the financial statements of foreignnoperations -5897000.00 -5897000.00 0.00